Clindamycin (** Cleocin, Dalacin, Clindesse, ClindaMax (Generic: Clindamycin) **)
Other Medications
Description
Clindamycin is not used in the treatment of colorectal cancer (CRC). It is primarily indicated for the treatment of bacterial infections. Its mechanism of action does not target cancer cells, and it has no clinical utility in CRC therapy.
Mechanism of Action
Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, thereby preventing peptide bond formation and subsequent elongation of protein synthesis on the ribosome.
Side Effects
Gastrointestinal distress; diarrhea; pseudomembranous colitis; Clostridium difficile-associated diarrhea; skin reactions; anaphylaxis
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
NCT01874860
med_phase_prefix2
Archived
Skin Rash Study Before Chemotherapy in Colorectal & Head and Neck Cancer Patients
United States